Get started
RELIEF THERAPEUTICS NRR

RELIEF THERAPEUTICS N

2.73CHFD
−0.02−0.73%
At close at 22:50 GMT
CHF
No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

RLF trade ideas

RLF - Worth a buy?RLF seemingly had a very volatile few months, which is not unlikely for penny stocks. The recent pullback could offer some decent entry levels for the brave however. Technically we're looking at a sharp gap lower at the end of the year with a subsequent rebound that recovered around 75% of the losses so far. Trading volume and volatility have decreased drastically since and the recent small gap higher on positive momentum looks promising. The 0.30 level seems to form a support level, next resistance is at 0.3375 and then at 0.35 (i.e. the trading level before the new year drop off). Any positions engaged now would require the stock to surpass the resistance by quite a margin to have a worthwhile risk-reward ratio. I will be looking at a small position with a tight SL in the 0.275 area and subsequently raise the bar if the stock moves higher. Buy Limit 0.3050, GTD SL 0.2750 Take Profit 0.3900
SLong
by SLRK
2
RLFTF and the SCIENCE behind the chartThis stock has been interesting to watch from a market perspective. There are 2.5Bn shares out there, major institutional holders, insiders buy in. But what fascinates me most, is two fold. The first is the science and open label study results. The second is the people, the team behind the science. Do your own DD, but you will find the same results. A team of doctors from large big pharma companies, with the experience to lead a drug through the FDA approval cycle. This is a juicy one so , grab a few thousand and hang on for the ride.
OLong
by michaelquale
2
$RLFTF Relief Therapeutics 50% Potential UpsideCompany Details RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. It engages in the development and licensing of its portfolio of medicinal products candidates. Its products include aviptadil, for respiratory indications such as sarcoidosis and pulmonary hypertension; and atexakin alfa, for the treatment of diabetic neuropathy. The company was founded in June 2016 and is headquartered in Geneva, Switzerland.
OLong
by OTCMarketsExpert
Real Company - Expecting GOOD returnsThis is a SWISS company trading in OTC but this is a REAL company with REAL DRUG. So They have an ED medication ( Aviptadil ) that hospitals might use for COVID patients with respiratory Failure They are on "FAST TRACK" For FDA Approval .20 cents is a good buy. I got in at .18 and sold and bought several times to make a profit today. but I am still in heavily. I would sell at .35 Cents if you wanna take profits. If FDA approves then I see it going high.... Volume is GOOD.
OLong
by satish-gaire
4
Rapid Recovery Respiratory Failure - COVID-19 TreatmentRelief Therapeutics Holding AG, a clinical stage biotechnology company, engages in developing treatment solutions for indications related to diabetic complications and respiratory diseases. The company is developing aviptadil, which has completed Phase II clinical trial for the treatment of sarcoidosis, an orphan pulmonary disease, as well as pulmonary hypertension; and atexakin alfa that has completed Phase I clinical trial to treat peripheral diabetic neuropathy. Relief Therapeutics Holding AG is based in Geneva, Switzerland. RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells - Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites - Aviptadil is being developed as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes - RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol finance.yahoo.com I think this stock could spike like Moderna Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
OLong
by HotCharts
1
Swiss Penny Stock - Rather neutral, could surge but...RSI showing bullish sign, but nothing show the bulls are accumulating positions according to Net volume and Aroon.... Should check fudamentals too... ********DISCLAIMER******** Hello guys, posting these analysis publicly to share my trading ideas with my classmates. These ideas are normally made for my own usage and published as private, but I'm posting them publicly as part of a group work about stock trading... At no moment ever are my comments and/or charts claiming to be accurate advices about stock markets. I'm just a random guy interested by financial markets, not a certified advisor. Consider my observations accordingly... ***************************
S
by Morchella
1